Decisions Home

United Kingdom Epigenetics Market Insight

Published: 02 July 2026   |   Report Format: Electronic (PDF)   |   Author: Govind and Krishna

The United Kingdom Epigenetics Market is projected to grow at a CAGR of around 14.2% from 2025 to 2035, driven by increasing investments in precision medicine, expanding cancer research activities, growing adoption of epigenetic biomarkers, and rising demand for advanced genomic technologies across clinical and research settings.

United Kingdom Epigenetics Market Forecasts to 2035

  • The United Kingdom Epigenetics Market Size was estimated at USD 0.72 Billion in 2025.
  • The market is expected to grow at a CAGR of around 14.2% from 2025 to 2035.
  • The United Kingdom Epigenetics Market Size is expected to reach around USD 2.71 Billion by 2035.

Notable Insights for the United Kingdom Epigenetics Market

  •  Segmentation based on product type, including reagents, kits, enzymes, instruments, and bioinformatics tools, accounted for nearly 68% of the market share in 2025, supported by increasing utilization of sequencing technologies and molecular diagnostics.
  • Segmentation based on application, including oncology, developmental biology, metabolic diseases, and drug discovery, represented approximately 72% of the market share in 2025, owing to growing emphasis on personalized medicine and translational research initiatives.
  • The United Kingdom Epigenetics Market is supported by Thermo Fisher Scientific Inc., Illumina Inc., and Agilent Technologies Inc., which generated revenues of approximately USD 43.18 billion, USD 4.53 billion, and USD 6.95 billion, reflecting sustained investments in genomics, sequencing platforms, and epigenetic research capabilities.
  • Danaher Corporation, Merck KGaA, and Bio-Rad Laboratories Inc. reported revenues of approximately USD 23.88 billion, USD 23.24 billion, and USD 2.67 billion, highlighting continued innovation in life science instruments, molecular biology solutions, and epigenetic assay development.

Download the eBook (ToC)

We value your privacy.

Why Buy This Report

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom epigenetics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

Top Companies in United Kingdom Epigenetics Market

• Thermo Fisher Scientific Inc.

• Illumina Inc.

• Agilent Technologies Inc.

• Danaher Corporation

• Merck KGaA

• Bio-Rad Laboratories Inc.

• QIAGEN N.V.

• PerkinElmer Inc.

• Pacific Biosciences Inc.

• Oxford Nanopore Technologies plc.

 

 

Recent Developments:

 

Market Segmentation:

United Kingdom Epigenetics Market, By Product Type

• Reagents

• Kits

• Enzymes

• Instruments

• Software and Bioinformatics Tools

 

United Kingdom Epigenetics Market, By Technology

• DNA Methylation

• Histone Modification

• Chromatin Remodeling

• Non-coding RNA Analysis

 

United Kingdom Epigenetics Market, By Application

• Oncology

• Metabolic Diseases

• Developmental Biology

• Cardiovascular Diseases

• Drug Discovery and Development

 

United Kingdom Epigenetics Market, By End User

• Academic and Research Institutes

• Pharmaceutical Companies

• Biotechnology Companies

• Clinical Laboratories

• Contract Research Organizations

 

United Kingdom Epigenetics Market, By Region

• England

• Scotland

• Wales

• Northern Ireland

 

Expert Views:

The United Kingdom epigenetics market is anticipated to witness robust growth through 2035, supported by increasing adoption of precision medicine, expanding genomic research programs, and rising investments in advanced molecular diagnostics. Technological advancements in sequencing platforms, biomarker identification, and epigenetic therapeutics are expected to strengthen market expansion. Companies emphasizing innovation, strategic collaborations, and next-generation analytical solutions are likely to enhance their competitive position while addressing evolving healthcare and research requirements across the United Kingdom.


Author: Govind and Krishna By Decisions Advisors and Consulting